The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Outcomes of the study combining necitumumab and abemaciclib in patients with NSCLC
Benjamin Besse, MD, PhD from the Institute Gustave Roussy, Villejuif, France, discusses the outcomes of the recent phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer (NCT02411591). Speaking at the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Dr Besse outlines the two phases of the study to investigate both the toxicity and efficacy of the combination therapy.
